title: Local estrogen replacement therapy in postmenopausal atrophic vaginitis: efficacy and safety of low dose 17beta-estradiol vaginal tablets.
abstract: OBJECTIVE
  To verify the effectiveness and safety of low-dose 17beta-estradiol vaginal tablets in the treatment of the postmenopausal atrophic vaginitis.
  
  
  METHODS
  325 postmenopausal women with atrophic vaginitis in estrogenic replacement therapy with 0.025 mg 17beta-estradiol vaginal tablets, one application each day for two weeks, and a single application two times a week for the following 22 weeks (total treatment period: 24 weeks).
  
  
  RESULTS
  Most of the women reported an improvement of symptoms just after two weeks and minimal incidence of adverse reactions. No patients showed abnormal endometrial thickness and no one had to interrupt the treatment for abnormal uterine bleeding because of systemic absorption.
  
  
  CONCLUSIONS
  Low-dose 17beta-estradiol vaginal tablets in the treatment of the postmenopausal atrophic vaginitis constitutes an extremely valid approach in terms of effectiveness and safety.
authors.affiliation: Department of Gynaecologic Obstetric and Reproduction Sciences, Second University of Naples, Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Mainini
authors.forename: C
authors.initials: C
authors.lastname: Scaffa
authors.forename: M
authors.initials: M
authors.lastname: Rotondi
authors.forename: E M
authors.initials: EM
authors.lastname: Messalli
authors.forename: L
authors.initials: L
authors.lastname: Quirino
authors.forename: A
authors.initials: A
authors.lastname: Ragucci
mesh_terms: D000282:Administration, Intravaginal; D000368:Aged; D001284:Atrophy / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004958:Estradiol / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D020249:Hormone Replacement Therapy; D006801:Humans; D008875:Middle Aged; D017060:Patient Satisfaction; D017698:Postmenopause; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014627:Vaginitis / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D004958:Estradiol